合并慢性肾脏病与心房颤动患者的抗凝治疗:JACC综述
心房颤动(AF)与慢性肾脏病(CKD)常因高血压、糖尿病和冠心病等共同风险因素而并存。在晚期CKD中,抗凝决策存在争议,因缺血性卒中与出血风险随肾功能下降而增加,且缺乏随机对照试验证据,观察性研究结果矛盾。本综述阐述病理生理机制,总结有限数据,并提出是否及如何使用口服抗凝药的决策方法。
要点
- AF与CKD常共存,共享高血压、糖尿病和冠心病等风险因素。
- 晚期CKD中抗凝决策困难,缺血性卒中与出血风险均随肾功能下降而增加。
- 缺乏随机对照试验指南,观察性研究结果矛盾,需个体化决策。
核心结论
- 在合并CKD的AF患者中,抗凝决策需权衡缺血性卒中与出血风险,目前缺乏随机对照试验证据,观察性研究结果矛盾。
研究设计与样本
- 综述文章,未报告系统检索范围或样本量。
主要发现
- AF与CKD常共存,共享高血压、糖尿病和冠心病等风险因素。
- 随着肾功能下降,缺血性卒中和出血风险均进行性增加。
- 缺乏来自随机对照试验的明确临床指南,观察性研究结果矛盾。
临床怎么用
- 综述建议根据病理生理机制和现有有限数据,个体化评估是否及如何使用口服抗凝药。
局限性
- 缺乏随机对照试验证据,现有观察性研究结果矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist as they share multiple risk factors, including hypertension, diabetes mellitus, and coronary artery disease. Although there is irrefutable evidence supporting anticoagulation in AF in the general population, these data may not be transferable to the setting of advanced CKD, where the decision to commence anticoagulation poses a conundrum. In this cohort, there is a progressively increased risk of both ischemic stroke and hemorrhage as renal function declines, complicating the decision to initiate anticoagulation. No definitive clinical guidelines derived from randomized controlled trials exist to aid clinical decision-making, and the findings from observational studies are conflicting. In this review, the authors outline the pathophysiological mechanisms at play and summarize the limited existing data related to anticoagulation in those with concomitant CKD and AF. Finally, the authors suggest how to approach the decision of whether and how to use oral anticoagulation in these patients.
引用
- Kumar S, Lim E, Covic A, et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019. PMID: 31648714. doi:10.1016/j.jacc.2019.08.1031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。